Novartis Global Pipeline
Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.
Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.
For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2017.
Please note: the Novartis Pipeline data is updated quarterly.
Arzerra®
ofatumumab
Refractory indolent non-Hodgkin’s lymphoma
Oncology
Phase III
2020
Anti-CD20 monoclonal antibody
BAF312
siponimod
Secondary progressive multiple sclerosis
Neuroscience
Registration
Sphingosine-1-phosphate receptor modulator
BYL719
alpelisib
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (postmenopausal women), 2nd line (+ fulvestrant)
Oncology
Phase III
2018
PI3Kα inhibitor
BYM338
bimagrumab
Sarcopenia
Neuroscience
Phase II
>=2022
Inhibitor of activin receptor Type 2
BYM338
bimagrumab
Hip fracture recovery
Neuroscience
Phase II
>=2022
Inhibitor of activin receptor Type 2
CAD106
amilomotide
Alzheimer’s disease
Neuroscience
Phase II
>=2022
Beta-amyloid-protein therapy
CFZ533
–
Sjorgen’s Syndrome
Immunology and Dermatology
Phase II
>=2022
CFZ533
–
Solid organ transplantation
Immunology and Dermatology
Phase II
>=2022
Blocking, non-depleting, anti-CD40 monoclonal antibody
CNP520
–
Alzheimer’s disease
Neuroscience
Phase II
>=2022
BACE inhibitor
CSJ117
–
Severe Asthma
Respiratory
Phase II
>=2022
Inhaled anti-Thymic Stromal LymphoPoetin cytokine antibody fragment
Pages
Legend
|
|
||||||||||||||||||||||||
Disclaimer
This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.
In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.